Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-09-13

Clinical Trial Update: Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in China

View source ↗

Summary

A completed real-world outcome study evaluating adalimumab in Chinese patients with rheumatoid arthritis, with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ADALIMUMAB (ADALIMUMAB-AATY)

Snippet

Sponsor: AbbVie | Conditions: Rheumatoid Arthritis | Status: COMPLETED | Results posted: 2019-09-13